UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 481

Sortiert nach

Antibody drug conjugates: lessons from 20 years of clinical experience

Annals of oncology, 2016-12, Vol.27 (12), p.2168-2172

Tolcher, A.W.

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Annals of oncology, 2010-02, Vol.21 (2), p.376-381

2010

Link zum Volltext

Verfügbarkeit prüfen

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

British journal of cancer, 2011-09, Vol.105 (7), p.938-944

2011

Link zum Volltext

Verfügbarkeit prüfen

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Annals of oncology, 2016-10, Vol.27 (10), p.1928-1940

2016

Link zum Volltext

Verfügbarkeit prüfen

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Annals of oncology, 2016-03, Vol.27 (3), p.526-532

2016

Link zum Volltext

Verfügbarkeit prüfen

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

Cancer chemotherapy and pharmacology, 2012-08, Vol.70 (2), p.305-313

2012

Link zum Volltext

Verfügbarkeit prüfen

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of oncology, 2015-01, Vol.26 (1), p.58-64

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

Annals of oncology, 2012-04, Vol.23 (4), p.968-973

2012

Link zum Volltext

Verfügbarkeit prüfen

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

British journal of cancer, 2017-11, Vol.117 (11), p.1592-1599

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α₅β₁ integrin monoclonal antibody (volociximab) in cancer patients

Cancer chemotherapy and pharmacology, 2010, Vol.65 (2), p.207-217

2010

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Annals of oncology, 2004-12, Vol.15 (12), p.1825-1833

2004

Link zum Volltext

Verfügbarkeit prüfen

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Blood, 1997-07, Vol.90 (1), p.244-251

1997

Link zum Volltext

Verfügbarkeit prüfen

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer

Annals of oncology, 2006-02, Vol.17 (2), p.313-321

2006

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

Annals of oncology, 2019-02, Vol.30 Suppl 1, p.i2

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii409-viii409

2018

Link zum Volltext

Verfügbarkeit prüfen

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii138

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii144

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO open, 2024-04, Vol.9 (4), p.102961-102961, Article 102961

2024

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer

Clinical cancer research, 2001-12, Vol.7 (12), p.3920-3927

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1173-1184

1996

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties

Journal of clinical oncology, 2001-06, Vol.19 (11), p.2937-2947

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

Journal of clinical oncology, 1996-04, Vol.14 (4), p.1185-1191

1996

Link zum Volltext

Verfügbarkeit prüfen

BR96-doxorubicin: been there, done that

Journal of clinical oncology, 2000-12, Vol.18 (23), p.4000

Tolcher, A W

2000

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors

Annals of oncology, 2000-03, Vol.11 (3), p.333-338

2000

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 481

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(475)
Mit Volltextzugriff
(459)

Publikationsform

Artikel
(478)
Tagungsberichte
(3)

Sprache

Englisch
(481)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antibody drug conjugates: lessons from 20 years of clinical experience

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α₅β₁ integrin monoclonal antibody (volociximab) in cancer patients

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer

A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors

First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies

Safety and efficacy of the PD-1 inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary phase I results from study M15-891

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer

Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer

Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties

Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer

BR96-doxorubicin: been there, done that

A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors

Suchergebnisse filtern